These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32664968)

  • 1. Next generation sequencing to decipher concurrent loss of PMS2 and MSH6 in colorectal cancer.
    Moreno E; Rosa-Rosa JM; Caniego-Casas T; Ruz-Caracuel I; Perna C; Guillén C; Palacios J
    Diagn Pathol; 2020 Jul; 15(1):84. PubMed ID: 32664968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal cancer in Lynch syndrome associated with PMS2 and MSH6 mutations.
    Yılmaz A; Mirili C; Bilici M; Tekin SB
    Int J Colorectal Dis; 2020 Feb; 35(2):351-353. PubMed ID: 31845022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
    Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
    Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
    Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
    Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Background of Colorectal Tumors From Patients With Lynch Syndrome Associated With Germline Variants in PMS2.
    Ten Broeke SW; van Bavel TC; Jansen AML; Gómez-García E; Hes FJ; van Hest LP; Letteboer TGW; Olderode-Berends MJW; Ruano D; Spruijt L; Suerink M; Tops CM; van Eijk R; Morreau H; van Wezel T; Nielsen M
    Gastroenterology; 2018 Sep; 155(3):844-851. PubMed ID: 29758216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
    Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
    Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation.
    McCarthy AJ; Capo-Chichi JM; Spence T; Grenier S; Stockley T; Kamel-Reid S; Serra S; Sabatini P; Chetty R
    J Pathol Clin Res; 2019 Apr; 5(2):115-129. PubMed ID: 30387329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homozygous germ-line mutation of the PMS2 mismatch repair gene: a unique case report of constitutional mismatch repair deficiency (CMMRD).
    Ramchander NC; Ryan NA; Crosbie EJ; Evans DG
    BMC Med Genet; 2017 Apr; 18(1):40. PubMed ID: 28381238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MSH6 immunohistochemical heterogeneity in colorectal cancer: comparative sequencing from different tumor areas.
    Chen W; Pearlman R; Hampel H; Pritchard CC; Markow M; Arnold C; Knight D; Frankel WL
    Hum Pathol; 2020 Feb; 96():104-111. PubMed ID: 31783044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline mismatch repair gene variants analyzed by universal sequencing in Japanese cancer patients.
    Kiyozumi Y; Matsubayashi H; Horiuchi Y; Higashigawa S; Oishi T; Abe M; Ohnami S; Urakami K; Nagashima T; Kusuhara M; Miyake H; Yamaguchi K
    Cancer Med; 2019 Sep; 8(12):5534-5543. PubMed ID: 31386297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency.
    Pearlman R; Markow M; Knight D; Chen W; Arnold CA; Pritchard CC; Hampel H; Frankel WL
    Mod Pathol; 2018 Dec; 31(12):1891-1900. PubMed ID: 29967423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of
    Okkels H; Lagerstedt-Robinsson K; Wikman FP; Hansen TVO; Lolas I; Lindberg LJ; Krarup HB
    Genet Test Mol Biomarkers; 2019 Sep; 23(9):688-695. PubMed ID: 31433215
    [No Abstract]   [Full Text] [Related]  

  • 13. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
    Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
    Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
    [No Abstract]   [Full Text] [Related]  

  • 14. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas.
    Ju JY; Mills AM; Mahadevan MS; Fan J; Culp SH; Thomas MH; Cathro HP
    Am J Surg Pathol; 2018 Nov; 42(11):1549-1555. PubMed ID: 30148743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Universal screening to identify Lynch syndrome: two years of experience in a Northern Italian Center.
    Chiaravalli AM; Carnevali I; Sahnane N; Leoni E; Furlan D; Berselli M; Sessa F; Tibiletti MG
    Eur J Cancer Prev; 2020 Jul; 29(4):281-288. PubMed ID: 31609810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive molecular assessment of mismatch repair deficiency in Lynch associated ovarian cancers using next generation sequencing panel.
    Kim SR; Oldfield L; Tone A; Pollett A; Pedersen S; Wellum J; Cesari M; Lajkosz K; Pugh TJ; Ferguson SE
    Int J Gynecol Cancer; 2024 Feb; 34(2):267-276. PubMed ID: 37940339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
    Jin W; Wang LQ; Liu Y; Liu AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.
    Hall G; Clarkson A; Shi A; Langford E; Leung H; Eckstein RP; Gill AJ
    Pathology; 2010; 42(5):409-13. PubMed ID: 20632815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of CNV-neutral structural genomic rearrangements in MLH1, MSH2, and PMS2 not detectable in routine NGS diagnostics.
    Morak M; Steinke-Lange V; Massdorf T; Benet-Pages A; Locher M; Laner A; Kayser K; Aretz S; Holinski-Feder E
    Fam Cancer; 2020 Apr; 19(2):161-167. PubMed ID: 32002723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.